Fate Therapeutics
FATE
22 hedge funds and large institutions have $62.4M invested in Fate Therapeutics in 2014 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
5% more funds holding
Funds holding: 21 → 22 (+1)
33% less capital invested
Capital invested by funds: $92.8M → $62.4M (-$30.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$593K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$535K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$513K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$360K |
| 5 |
Goldman Sachs
New York
|
+$293K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
U
UBS
Zurich,
Switzerland
|
-$250K |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$189K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$97K |
| 4 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$77.3K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$10K |
FATE Hedge Fund Activity: Q2 2014 in Review
22 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2014, worth a combined $62.4M — down 33% from $92.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new FATE positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Kingdon Capital Management, adding an estimated $593K. The largest seller was UBS, exiting entirely with an estimated $250K sold.
- 22 institutional investors held Fate Therapeutics (FATE) as of Q2 2014, up from 21 in Q1 2014.
- Funds reported $62.4M of Fate Therapeutics stock for Q2 2014, down 33% quarter-over-quarter.
- 6 funds opened new Fate Therapeutics positions in Q2 2014 and 5 closed out, a net change of +1 holder.
- The largest Fate Therapeutics buyer in Q2 2014 was Kingdon Capital Management, an estimated $593K added.
- The largest Fate Therapeutics seller in Q2 2014 was UBS, an estimated $250K sold.
Based on aggregated 13F filings for Q2 2014.